The drug may slow the progression of Alzheimer’s disease, but it doesn’t improve the symptoms. It’s also incredibly expensive.
Articles on Lecanemab
Displaying all articles
When is it right to reject an expensive new drug?
There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for Nice’s decision.
Confused by conflicting studies about the link between viagra and Alzheimer’s? Two experts explain the disparaties
Despite decades of starts and stops, new treatments and key genetic discoveries are giving researchers great hope for slowing or eventually preventing Alzheimer’s disease.
In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.
An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.
Two new dementia drugs are being hailed as breakthroughs. But what might be an incremental breakthrough for researchers, doesn’t mean a cure for patients.
Lecanemab slows progression of early-stage Alzheimer’s disease in some, new study shows. But the ‘adverse events’ are significant.
Lecanemab, an experimental dementia drug, slowed cognitive decline by 27% in late-stage clinical trials.
Top contributors
-
Professor in Clinical Pharmacy, Aston University
-
Post Doctoral Research Assistant, University of Bradford
-
Director of Research, Associate Professor in Therapeutics, University of Bradford
-
Clinical Professor of Ageing, Queen's University Belfast
-
Étudiant au doctorat en psychologie, Université du Québec à Montréal (UQAM)
-
Professor of Neurology, University of Miami
-
Associate Professor in Dementia Neurology, University of Bristol
-
Professor of Neurology and Neuroscience, University of Florida
-
Associate Professor, Turner Institute for Brain and Mental Health, Monash University
-
Professeur, Université Laval
-
Senior lecturer in Pharmacoepidemiology, Aston University
-
Chair Professor, Health Policy and History, University of Liverpool
-
Senior Research Fellow, History of Health and Medicine, University of Liverpool
-
Postdoctoral Research Fellow (Neuropsychology), Monash University
-
Head of Clinical Services, Dementia Support Australia, & Associate Professor of Psychiatry, Monash University